| Autor: |
Paola Queirolo, Rita Chiari, Pietro Di Marino, Maria Vitale, Francesco Grossi, Sebastiano Buti, Vincenzo Adamo, Maria Giuseppa Vitale, David J. Pinato, Serena Macrini, Marco Russano, Fabrizio Citarella, Alessandro Russo, Melissa Bersanelli, Olga Nigro, Michele Ghidini, Linda Nicolardi, Marco Ferrari, Maria Chiara Sergi, Giampiero Porzio, Luigia Stefania Stucci, Francesco Spagnolo, Michele De Tursi, Daniele Santini, Corrado Ficorella, Andrea Botticelli, Marco Tucci, Paolo A. Ascierto, Paolo Marchetti, Sergio Bracarda, Raffaele Giusti, Laura Pala, Marco Siringo, Domenico Mallardo, Giulia Mazzaschi, Riccardo Marconcini, Stefania Gori, Alessio Cortellini, Enrica Teresa Tanda, Alain Gelibter, Cecilia Anesi, Francesca Rastelli, Federica Zoratto, Francesca Giorgi, Thomas Talbot, Marco Filetti, Alessandro Inno, Tea Zeppola |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Journal of Translational Medicine
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-8 (2021) |
| ISSN: |
1479-5876 |
| Popis: |
Background The favourable safety profile and the increasing confidence with immune checkpoint inhibitors (ICIs) might have boosted their prescription in frail patients with short life expectancies, who usually are not treated with standard chemotherapy. Methods The present analysis aims to describe clinicians’ attitudes towards ICIs administration during late stages of life within a multicenter cohort of advanced cancer patients treated with single agent PD-1/PD-L1 checkpoint inhibitors in Italy. Results Overall, 1149 patients with advanced cancer who received single agent PD-1/PD-L1 checkpoint inhibitors were screened. The final study population consisted of 567 deceased patients. 166 patients (29.3%) had received ICIs within 30 days of death; among them there was a significantly higher proportion of patients with ECOG-PS ≥ 2 (28.3% vs 11.5%, p Conclusion Our results confirmed a trend toward an increasing ICIs prescription in frail patients, during the late stages of life. Caution should be exercised when evaluating an ICI treatment for patients with a poor PS and a high burden of disease. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
